Majedie Asset Management’s Amgen AMGN Stock Holding History

Majedie Asset Management’s Portfolio AMGN Stock Details AMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-3,600	Closed	-$573K	–	65
2014 Q4	$573K	Sell	3,600 -1,793	-33%	-$279K	0.11%	44
2014 Q3	$758K	Buy	5,393 +1,438	+36%	+$188K	0.13%	31
2014 Q2	$468K	Buy	+3,955	New	+$458K	0.11%	22

Other funds holding AMGN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Majedie Asset Management's AMGN Position: Q1 2015 in Review

Majedie Asset Management sold out of Amgen (AMGN) in Q1 2015, closing a stake of 3,600 shares — an estimated $573K sold.

Majedie Asset Management first reported a position in AMGN in Q2 2014 and held it in 3 quarters. The position peaked at $758K in Q3 2014. 1,344 funds tracked by Wall St. Rank hold AMGN as of Q1 2015.

Majedie Asset Management reported no remaining Amgen position as of Q1 2015 after selling out during the quarter.
Majedie Asset Management sold 3,600 Amgen shares in Q1 2015, an estimated $573K.
Majedie Asset Management first reported a position in Amgen in Q2 2014 and held it in 3 quarters.
Majedie Asset Management's Amgen position peaked at $758K in Q3 2014.
1,344 funds tracked by Wall St. Rank held Amgen as of Q1 2015.

Based on Majedie Asset Management's 13F filing for Q1 2015, filed 8 May 2015.